NCT01604889 2026-04-21
A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma
Incyte Corporation
Phase 1/2 Terminated
Incyte Corporation
CytomX Therapeutics
CytomX Therapeutics
GlaxoSmithKline
Jounce Therapeutics, Inc.
SQZ Biotechnologies
RAPT Therapeutics, Inc.
Bristol-Myers Squibb
Bristol-Myers Squibb
Ludwig Institute for Cancer Research
AbbVie